México Diagnóstico del Cáncer Mercado Tamaño, Participación, Tendencias y Pronóstico por Producto, Tecnología, Aplicación, Usuario Final y Región, 2026-2034

Overview of the cancer diagnostics market in Mexico:

The cancer diagnostics market in Mexico reached USD 2.6 billion in 2025. Looking ahead, IMARC Group expects the market to reach USD 4.0 billion by 2034 , exhibiting a compound annual growth rate (CAGR) of 4.54% during 2026-2034 . The market is experiencing steady growth, driven by advancements in diagnostic technologies, the expansion of healthcare infrastructure, and increased awareness of early cancer detection. The rising prevalence of cancer cases, various government initiatives, and innovations in molecular diagnostics, imaging technologies, and personalized medicine are some of the factors further driving the growth of the cancer diagnostics market in Mexico.

Trends in the cancer diagnostics market in Mexico:

Increased incidence of cancer

Mexico is experiencing a significant increase in cancer cases, driven by lifestyle changes, greater exposure to risk factors, and an aging population. The prevalence of common cancers such as breast, colorectal, and lung cancer is rising, creating an urgent need for early detection and accurate diagnostic tools. According to data published by the OECD, cancer is the fourth leading cause of death in Mexico, contributing to 1 in 14 premature deaths. By 2050, there will be approximately 46,200 premature cancer deaths annually, reducing life expectancy by 0.9 years. Improved cancer care could prevent 50% of these deaths and increase life expectancy by 5 months. Early detection is crucial for improving survival rates and treatment outcomes, making the need for cutting-edge diagnostic technologies rapidly growing. Advances in imaging technologies such as magnetic resonance imaging (MRI) and positron emission tomography (PET), as well as molecular diagnostics and genetic testing, are increasingly being used to diagnose cancers at early stages. Governments and healthcare systems are prioritizing increased access to these technologies, particularly in underserved areas. As cancer rates continue to rise, effective diagnostic tools are becoming increasingly essential for the Mexican healthcare sector, further increasing market demand.

Technological advances

Technological advancements are playing a crucial role in the growth of cancer diagnostics in Mexico. Innovations such as molecular diagnostics, liquid biopsy, and advanced imaging technologies are revolutionizing early detection and treatment planning. For example, in July 2023, BPGbio announced its partnership with Grupo Terralpe to launch the innovative pstateDx™ prostate cancer diagnostic test in Mexico. This AI-discovered, non-PSA blood test distinguishes between aggressive prostate cancer and benign prostatic hyperplasia, potentially reducing unnecessary biopsies. The test is BPGbio's first commercial product from its Interrogative Biology platform.

Molecular diagnostics allows for the detection of genetic mutations and biomarkers associated with certain types of cancer, facilitating improved diagnosis and more targeted treatment. Liquid biopsy, in which blood samples are examined for cancer-specific genetic material, is proving to be a non-invasive alternative to conventional biopsy procedures, providing a faster and safer method for detecting cancers at an early stage. Likewise, imaging technologies such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) are improving, offering clearer and more precise tumor identification. These advancements are significantly increasing diagnostic accuracy, resulting in better outcomes for patients. Consequently, the cancer diagnostics market in Mexico is expected to continue growing as the adoption of these technologies becomes more widespread.

Segmentation of the cancer diagnostics market in Mexico:

IMARC Group offers an analysis of key trends in each market segment, along with national and regional forecasts for 2026-2034. Our report has categorized the market based on product, technology, application, and end user.

Product Perspectives:

• Consumables
  • Antibodies
  • Kits and reagents
  • Probes
  • Others
• Instruments
  • Pathology-based instruments
  • Imaging instruments
  • Biopsy instruments

The report offers a detailed breakdown and analysis of the market by product. This includes consumables (antibodies, kits and reagents, probes, and others) and instruments (pathology-based instruments, imaging instruments, and biopsy instruments).

Technological perspectives:

• IVD Tests
  • Polymerase chain reaction (PCR)
  • In situ hybridization (ISH)
  • Immunohistochemistry (IHC)
  • Next-generation sequencing (NGS)
  • Microarrays
  • Flow cytometry
  • Immunoassays
  • Others
• Images
  • Magnetic resonance imaging (MRI)
  • Computed tomography (CT)
  • Positron emission tomography (PET)
  • Mammography
  • Ultrasound
• Biopsy technique

The report also provides a detailed breakdown and analysis of the market based on technology. This includes IVD testing (polymerase chain reaction [PCR], in situ hybridization [ISH], immunohistochemistry [IHC], next-generation sequencing [NGS], microarrays, flow cytometry, immunoassays, and others), diagnostic imaging (magnetic resonance imaging [MRI], computed tomography [CT], positron emission tomography [PET], mammography, and ultrasound), and biopsy techniques.

Application perspectives:

• Breast cancer
• Lung cancer
• Colorectal cancer
• Melanoma
• Others

The report also provides a detailed breakdown and analysis of the market based on application. This includes breast cancer, lung cancer, colorectal cancer, melanoma, and others.

End-user perspectives:

• Hospitals and clinics
• Diagnostic laboratories
• Others

The report also provides a detailed breakdown and analysis of the market based on end user, including hospitals and clinics, diagnostic laboratories, and others.

Regional perspectives:

• Northern Mexico
• Central Mexico
• Southern Mexico
• Others

The report also provided a comprehensive analysis of key regional markets, including northern Mexico, central Mexico, southern Mexico, and others.

Competitive landscape:

The market research report also provides a comprehensive analysis of the competitive landscape. This includes competitive analysis such as market structure, key player positioning, leading winning strategies, a competitive dashboard, and a company assessment quadrant. Detailed profiles of the top companies are also provided.

News from the cancer diagnostics market in Mexico:

• In March 2025, Longevity Medical Institute announced its partnership with OncoInv to launch an advanced cancer screening program in Mexico using OncoSeek® technology. The program improves the early detection of more than 12 types of cancer through a robust panel of biomarkers, offering a proactive and personalized healthcare approach for adults 50 and older.
• In January 2025, the Mexican Social Security Institute (IMSS) announced plans to improve cancer diagnostic services nationwide through a new agreement with IMSS-Bienestar. Focusing on breast cancer and childhood leukemia, the initiative allows local medical units to send samples for rapid diagnosis at the Eastern Biomedical Research Center, improving access for uninsured patients.
• In January 2025, Leica Biosystems announced a strategic investment in Indica Labs to accelerate AI-based cancer diagnostics. The partnership will launch a digital pathology platform that combines Leica's Aperio scanner with Indica's HALO AP software, improving primary diagnosis and enabling the integration of AI applications, ultimately enhancing patient access to therapies.

Coverage of the report on the cancer diagnostics market in Mexico:

Key questions answered in this report:

• How has the cancer diagnostics market in Mexico performed so far, and how will it perform in the coming years?
• What is the distribution of the Mexican cancer diagnostics market by product?
• What is the breakdown of the cancer diagnostics market in Mexico based on technology?
• What is the breakdown of the cancer diagnostics market in Mexico based on the end user?
• What is the breakdown of the cancer diagnostics market in Mexico by application?
• What is the breakdown of the cancer diagnostics market in Mexico by region?
• What are the different stages of the value chain in the cancer diagnostics market in Mexico?
• What are the main driving factors and challenges in cancer diagnosis in Mexico?
• What is the structure of the cancer diagnostics market in Mexico and who are its main players?
• What is the level of competition in the cancer diagnostics market in Mexico?

Main benefits for stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and market dynamics for cancer diagnostics in Mexico from 2020 to 2034.
• The research report provides the latest information on market drivers, challenges, and opportunities in the cancer diagnostics market in Mexico.
• Porter's Five Forces analysis helps stakeholders assess the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the cancer diagnostics industry in Mexico and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of the major market players.